<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2496">
  <stage>Registered</stage>
  <submitdate>17/09/2009</submitdate>
  <approvaldate>17/09/2009</approvaldate>
  <nctid>NCT00979368</nctid>
  <trial_identification>
    <studytitle>Safety Study of BMS-816336 in Healthy Male Subjects</studytitle>
    <scientifictitle>Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MB124-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Non-Insulin-Dependent</healthcondition>
    <healthcondition>Dyslipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-816336
Treatment: drugs - BMS-816336
Treatment: drugs - BMS-816336
Treatment: drugs - BMS-816336
Treatment: drugs - BMS-816336
Treatment: drugs - Placebo

Active Comparator: BMS-816336 or placebo (Panel 1) - 

Active Comparator: BMS-816336 or placebo (Panel 2) - 

Active Comparator: BMS-816336 or placebo (Panel 3) - 

Active Comparator: BMS-816336 or placebo (Panel 4) - 

Active Comparator: BMS-816336 or placebo (Panel 5) - 


Treatment: drugs: BMS-816336
Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days

Treatment: drugs: BMS-816336
Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days

Treatment: drugs: BMS-816336
Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days

Treatment: drugs: BMS-816336
Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days

Treatment: drugs: BMS-816336
Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days

Treatment: drugs: Placebo
Suspension, Oral, 0 mg, Once on Day 1 only, 4 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Exposure to the investigational drug will be measured to assess safety and tolerability</outcome>
      <timepoint>Within 72 hours following dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the single dose Pharmacokinetics of BMS-816336</outcome>
      <timepoint>During 72 hours following dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male subjects

          -  BMI of 18 to 32 kg/m²

          -  Men only, ages 18-55 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Sexually active men not using effective birth control if their partners are WOCBP

          -  Any significant acute or chronic medical illness

          -  Family history of Gilbert's disease

          -  History of Pancreatitis

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, EGG or clinical laboratory determinations

          -  QTc interval &gt; 450 msec (corrected for heart rate using Fridericia's correction
             method, QTcF)

          -  Second- or third-degree A-V block or clinically relevant ECG abnormalities

          -  History of allergy to 11-ß-HSD-1 inhibitors or related compounds

          -  Prior exposure to BMS-816336

          -  Use of St. John's Wort (Hypericum) within 4 weeks prior to the first dose of study
             drug and throughout the study

          -  Use of an oral, injectable, inhalable or suspension of glucocorticoid agents within 12
             weeks of study drug administration

          -  Use of any glucocorticoid topical creams within 4 weeks of study drug administration

          -  Use of oral, injectable, or topical androgen agent within 12 weeks prior to enrollment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Local Institution - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics
      following single oral doses of BMS-816336 in healthy male subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00979368</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>